The U.S. Food and Drug Administration (FDA) approved U.S. pharmaceutical giant Gilead Sciences’ “Remdesivir” as a new coronary treatment on October 22. It will be widely used in the future for patients who are admitted to hospitals. This is the first official approval of a new coronary therapy drug in the United States.
The Nihon Keizai Shimbun reported that the United States officially approved Remdesivir for use as a new coronary therapy drug. With the formal approval, it will be able to be used in adults or in hospitalized patients over 12 years of age and weighing more than 40 kg, the news release said. The effectiveness of raltegravir was confirmed in a clinical trial led by the National Institute of Allergy and Infectious Diseases (NIAID) in the United States. Results showed an average of 5 days earlier recovery for admitted patients.
Daniel O’Day, Chief Executive Officer (CEO) of Gilead, said, “Approved in less than a year from the initial case report of New Crown, raltegravir is available to patients in need.”
According to the report, raltegravir is an antiviral drug developed as a treatment for Ebola hemorrhagic fever. With its effectiveness against new coronaviruses confirmed, the U.S. Food and Drug Administration issued an emergency use authorization in May, allowing it to be used in patients admitted to the hospital with severe illness. The drug is also being used to treat President Trump, who is infected with the new strain. It was also approved in Japan on an exceptional basis for use as a neo-crown treatment in 50 countries worldwide. Gilead filed a formal application with the U.S. Food and Drug Administration in August.
On the other hand, the World Health Organization (WHO) released its findings on Oct. 15 that raltegravir was “largely or completely” ineffective in reducing mortality in patients with new crowns. In response, Gilead countered that the findings were “not subject to rigorous review.
Recent Comments